Engaging Community and Academic Physicians in Preparation for Product Launch
The Challenge
A biopharmaceutical company has in-licensed a new drug that gained FDA approval soon after the agreement went into effect. They want to build relationships with academic medical centers and community oncology practices to engage and educate key decision-makers relative to the drugs clinical data, in consideration of broad and appropriate access for patients with the specified indication.
The IP Solution
IP provided strategic support for the development and execution of 15 Institutional 1:1 Engagement Strategy and Meeting Management. Support for live meetings held over two consecutive days at a large national conference along with virtual meetings held by zoom after the conference. A summary report including physician biographies and a summary of each engagement with key take-aways, and action items was distributed to the company’s medical team and MSLs.
The Results
The company learned which data was viewed as most differentiating and compelling, key questions regarding the data and how treatment could be individualized based on molecular assessment of patients, and novel ways to present their data.
This project enabled access to the company’s corporate interests and product portfolio to the oncology stakeholder community. These engagements allowed the company to initiate discussion on new projects in niche areas that could be supported by the company. Many of the physicians expressed interest in collecting rea-world data and designing robust studies in other populations.
